Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 127
3 152
2 51
1 25
NEB 4
Curative setting
A 53
C 2
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 37
Endocrine Tumours 21
Gastrointestinal Cancers 69
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 11
Skin Cancers 29
TMB-H solid tumours 1
Thoracic Malignancies 82
Tumor agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 2
Skin Cancers 14
TMB-H solid tumours 0
Thoracic Malignancies 10
Tumor agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Nivolumab - Placebo Adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older. CHECKMATE-76K
    Skin Cancers
    		 Cutaneous Melanoma - CHECKMATE-76K

    A

    PRELIMINARY SCORE

    • RFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Encorafenib Binimetinib Single arm Encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation - previously treated PHAROS
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer BRAF V600E mutation PHAROS

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Encorafenib Binimetinib Single arm Encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation - treatment naïve PHAROS
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer BRAF V600E mutation PHAROS

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Docetaxel Oxaliplatin–S-1 + surgery + adjuvant S-1 Surgery + adjuvant S-1 Peri-operative therapy for the treatment of resectable advanced gastric cancer PRODIGY
    Gastrointestinal Cancers
    		 Gastric Cancer - PRODIGY

    A

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Cisplatin/S-1 - 5-FU + cisplatin First-line therapy for advanced gastric cancer FLAGS
    Gastrointestinal Cancers
    		 Gastric Cancer - FLAGS

    NEB

    PRELIMINARY SCORE

    • NEB

    ADJUSTMENTS

    SCORE

    • F2a
      NEB
    Toripalimab - Single arm Toripalimab as a single agent for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after a platinum-containing chemotherapy. POLARIS-02
    Head and neck cancer
    		 Nasopharyngeal carcinoma - POLARIS-02

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Fruquintinib Best supportive care Placebo + best supportive care Fruquintinib for adult patients with metastatic colorectal cancer (mCRC) who had disease progression during or after prior fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy. FRESCO
    Gastrointestinal Cancers
    		 Colorectal Cancer - FRESCO

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Fruquintinib Best supportive care Placebo + best supportive care Fruquintinib for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, if RAS wild-type and medically appropriate, an anti-EGFR therapy, and at least one of trifluridine/tipiracil or regorafenib. FRESCO -2
    Gastrointestinal Cancers
    		 Colorectal Cancer - FRESCO -2

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Tucatinib Trastuzumab Single arm Treatment of patients with RAS wild-type, HER2-positive unresectable or mCRC that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based ChT MOUNTAINEER
    Gastrointestinal Cancers
    		 Colorectal Cancer - MOUNTAINEER

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab Fluoropyrimidine and platinum-containing ChT Placebo + fluoropyrimidine and platinum-containing ChT Pembrolizumab with fluoropyrimidine and platinum-containing ChT for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. KEYNOTE-859
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma HER2- KEYNOTE-859

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Capivasertib Fulvestrant Placebo + fulvestrant Capivasertib with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy CAPItello-291
    Breast Cancer
    		 Breast Cancer PIK3CA/AKT1/PTEN- ; HR+ ; HER2- CAPItello-291

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pembrolizumab Gemcitabine and cisplatin Placebo + gemcitabine and cisplatin EMA: Pembrolizumab in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults. FDA: Pembrolizumab to be used with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966
    Gastrointestinal Cancers
    		 Biliary tract cancer - KEYNOTE-966

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Enfortumab vedotin Pembrolizumab Single arm For patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. EV-103/KEYNOTE-869
    Genitourinary Cancers
    		 Urothelial Carcinoma - EV-103/KEYNOTE-869

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Atezolizumab - ChT (vinflunine, paclitaxel or docetaxel) Treatment of patients with locally advanced or metastatic UC after prior platinum-containing ChT IMvigor211
    Genitourinary Cancers
    		 Urothelial Carcinoma - IMvigor211

    NEB

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      NEB
    Erdafitinib - ChT (docetaxel or vinflunine)  FDA: For adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy./ EMA: Erdafitinib as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting THOR/BLC3001 cohort 1
    Genitourinary Cancers
    		 Urothelial Carcinoma FGFR3 THOR/BLC3001 cohort 1

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Sacituzumab govitecan - Single arm Treatment of patients with locally advanced or metastatic UC who have previously received a platinum-containing ChT and either PD-1 or PD-L1 inhibitor  TROPHY-U-01
    Genitourinary Cancers
    		 Urothelial Carcinoma - TROPHY-U-01

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Enzalutamide Leuprolide Placebo + Leuprolide As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy. Combination group EMBARK
    Genitourinary Cancers
    		 Prostate cancer PSA doubling time ≤ 9 months EMBARK

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Durvalumab - Sorafenib Durvalumab as monotherapy indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC) HIMALAYA
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - HIMALAYA

    4

    PRELIMINARY SCORE

    • OS 

    ADJUSTMENTS

    SCORE

    • F2c
      4
    Nirogacestat - Placebo Nirogacestat for adult patients with progressing desmoid tumours who require systemic treatment. DeFi
    Non-cancerous soft-tissue tumour
    		 Desmoid (fibrous tissue) - DeFi

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Nivolumab Cisplatin-based ChT (Gemcitabine+Cisplatin) Standard of care chemotherapy (Gemcitabine+Cisplatin) Nivolumab in combination with cisplatin-based chemotherapy in the first-line setting for the treatment of patients with unresectable or metastatic urothelial carcinoma CHECKMATE-901
    Genitourinary Cancers
    		 Urothelial Carcinoma - CHECKMATE-901

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Eflornithine - Popensity score matched external control from ANBL0032. Matched cohort 3:1 Eflornithine to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. HRNB postimmunotherapy maintenance Study 3b, NMTRC003B - ANBL0032
    Brain Tumours
    		 Neuroblastoma - Study 3b, NMTRC003B - ANBL0032

    A

    PRELIMINARY SCORE

    • EFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Bevacizumab FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil) or CAPOX (Capecitabine) Placebo for Bevacizumab Treatment of patients with metastatic carcinoma of the colon or rectum  NO16966
    Gastrointestinal Cancers
    		 Colorectal Cancer - NO16966

    1

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      1
    Tislelizumab Pemetrexed + platinum‑containing ChT Pemetrexed + platinum‑containing ChT Tisleizumab in combination with pemetrexed and platinum‑containing ChT is indicated for the first-line treatment of adult patients with NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have: locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC RATIONALE 304
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations RATIONALE 304

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Tislelizumab - Docetaxel Tislelizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab. RATIONALE 303
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR and ALK positive RATIONALE 303

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Osimertinib Osimertinib ± Platinum Plus Pemetrexed ChT (Carboplatin, Cisplatin) Osimertinib FDA/EMA: Osimertinib with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. FLAURA 2
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR exon 19 deletions or exon 21 L858R mutations FLAURA 2

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Lifileucel - Single arm Treatment for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. LN-144
    Skin Cancers
    		 Melanoma - LN-144

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Irinotecan liposome Oxaliplatin, fluorouracil, and leucovorin Nab-paclitaxel + gemcitabine Irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma. NAPOLI 3
    Gastrointestinal Cancers
    		 Pancreatic cancer - NAPOLI 3

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Dab/Tram (dabrafenib and trametinib) - Single arm Adult and paediatric patients ≥1 year of age with unresectable or metastatic solid tumours with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options ROAR, NCI-MATCH (subprotocol H)
    Tumour agnostic
    		 - BRAF V600E mutated rare cancers ROAR, NCI-MATCH (subprotocol H)

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Enfortumab Pembrolizumab Platinum-based ChT FDA: Enfortumab vedotin in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer. EMA: Pembrolizumab, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults. EV-302/KN-A39
    Genitourinary Cancers
    		 Urothelial Carcinoma - EV-302/KN-A39

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Amivantamab Carboplatin and Pemetrexed Carboplatin and Pemetrexed FDA: Amivantamab with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. EMA: Amivantamab in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations PAPILLON
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ exon 20 insertion mutations PAPILLON

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.